Digital Patient Support Program for Self-efficacy and Medication Adherence in Women on Adjuvant Endocrine Treatment for Breast Cancer
Digital Patient Support Program for Self-Efficacy and Medication Adherence Amongst Women on Adjuvant Endocrine Treatment for Breast Cancer: A Randomized Controlled Trial
Sidekick Health
140 participants
May 31, 2025
INTERVENTIONAL
Conditions
Summary
This is a randomized, controlled study to assess the effect of Sidekick Health's digital program on self-efficacy and medication adherence in breast cancer patients prescribed adjuvant anti-hormonal treatment. Participants will be treated with the digital program in addition to standard of care (SoC), or SoC only.
Eligibility
Inclusion Criteria6
- Adult patient (18 years or older) diagnosed with breast cancer of stage I, II or III from 1st September 2023 or later
- Have been prescribed adjuvant endocrine therapy for breast cancer.
- Understands written and spoken Icelandic or English.
- Owns a smart-phone compatible with the Sidekick app and capable to use it
- Willing to download the Sidekick app on the smart-phone and to comply with the study measures and visits according to the protocol.
- Capable of providing informed consent for participating in the study.
Exclusion Criteria4
- Having other concurrent conditions that in the opinion of the oncologist may compromise patient safety or study objectives.
- Concurrent participation in another clinical study in which the study treatment may confound the evaluation of the investigational program.
- Metastatic breast cancer (stage IV)
- Previous experience with Sidekick breast cancer program
Interventions
A digital health program delivered through an app that provides holistic lifestyle intervention and medication adherence support.
Standard of care includes adjuvant breast cancer treatment and optional cancer rehabilitation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06989450